OncoPro检测报告

|  |  |  |  |
| --- | --- | --- | --- |
| **方案编号：** | **SHR-A2102-206** | **厦维项目编号：** | **XW0264** |

**送检信息**

|  |  |  |  |
| --- | --- | --- | --- |
| 受试者信息 | | | |
| 中心名称 | **{{sample.site\_name}}** | | |
| 受试者筛选号 | **{{sample.subject\_ID}}** | **疾病类型** | **{{sample.primary\_disease}}** |
| 性别 | **{%if sample.gender==”男”%}☑男 □女{%elif sample.gender==”女”%}□男 ☑女 {%else%}□男 □女 {%endif%}** | **出生年份** | **{{sample.birthday}}** |

|  |  |  |  |
| --- | --- | --- | --- |
| 样本信息 | | | |
| 样本编码 | **{{sample.specimen\_parent\_id}}** | **样本类型** | **血液** |
| 访视周期 | **{{sample.visit\_name}}** | **采集日期** | **{{sample.blood\_collection\_date}}** |
| 接收日期 | **{{sample.blood\_date\_received}}** | **报告日期** | **{{sample.report\_date}}** |
| 检测实验室名称 | **上海厦维医学检验实验室有限公司** | | |

**检测内容**

* **检测方法**

样本核酸提取后采用“人类多基因液体活检试剂盒”进行文库构建和目标区域捕获，测序平台为NovaSeq 6000，采用厦门艾德“人类癌症多基因突变分析软件”对检测数据进行分析。

* **检测范围**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **点突变与插入缺失变异的基因列表（99个基因）** | | | | | | | | | |
| *AKT1* | *AKT2* | *AKT3* | *ALK* | *APC* | *AR* | *ARAF* | *ARID1A* | *ATM* | *B2M* |
| *BARD1* | *BCL2L11* | *BRAF* | *BRCA1* | *BRCA2* | *BRIP1* | *CCND1* | *CCNE1* | *CDH1* | *CDK12* |
| *CDK4* | *CDK6* | *CDKN2A* | *CHEK1* | *CHEK2* | *CTNNB1* | *DDR2* | *EGFR* | *ERBB2* | *ERBB3* |
| *ESR1* | *EZH2* | *FANCA* | *FANCL* | *FBXW7* | *FGFR1* | *FGFR2* | *FGFR3* | *FGFR4* | *FH* |
| *GNA11* | *GNAQ* | *GNAS* | *HDAC2* | *HRAS* | *IDH1* | *IDH2* | *JAK1* | *JAK2* | *JAK3* |
| *KDR* | *KEAP1* | *KIT* | *KRAS* | *MAP2K1* | *MAP2K2* | *MAPK1* | *MAPK3* | *MDM2* | *MET* |
| *MLH1* | *MSH2* | *MSH6* | *MTAP* | *MTOR* | *MYC* | *NF1* | *NF2* | *NOTCH1* | *NRAS* |
| *NTRK1* | *NTRK2* | *NTRK3* | *PALB2* | *PDGFRA* | *PIK3CA* | *PIK3R1* | *PMS2* | *POLD1* | *POLE* |
| *PTEN* | *PTPN11* | *RAD51B* | *RAD51C* | *RAD51D* | *RAD54L* | *RAF1* | *RB1* | *RET* | *RICTOR* |
| *ROS1* | *SMAD4* | *SMO* | *STK11* | *TERT* | *TP53* | *TSC1* | *TSC2* | *VHL* |  |
| **检测融合变异的基因列表（21个基因）** | | | | | | | | | |
| *ALK* | *AR* | *BCL2L11* | *BRAF* | *CDH1* | *EGFR* | *ERBB2* | *ESR1* | *FGFR1* | *FGFR2* |
| *FGFR3* | *FGFR4* | *KIT* | *NRG1* | *NTRK1* | *NTRK2* | *NTRK3* | *PDGFRA* | *RAF1* | *RET* |
| *ROS1* |  |  |  |  |  |  |  |  |  |

* **检测局限性**

1. 本检测在DNA水平进行检测，检测的突变类型仅为点突变（SNV）、插入/缺失（InDel）及融合（Fusion）；不包含其他水平（如蛋白水平）的变异或其他类型的突变。
2. 阴性结果不能完全排除突变或融合基因的存在，样本中 cfDNA 过少，或文库中突变或融合的浓度低于检测限亦可造成阴性结果。
3. 若基因融合发生在高度重复区域中，则存在漏检的可能。

**检测结果**

* **SNV及InDel检测结果**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **基因** | | **变异类型** | | **转录本** | | **外显子/内含子** | **碱基变化** | | **氨基酸变化** | **突变丰度** | |
| {%tr if (var.var\_somatic.level\_I+var.var\_somatic.level\_II+var.var\_somatic.level\_onco\_nodrug)|filter\_snvindel%} | | | | | | | | | | | |
| {%tr for a in (var.var\_somatic.level\_I+var.var\_somatic.level\_II+var.var\_somatic.level\_onco\_nodrug)|filter\_snvindel%} | | | | | | | | | | | |
| *{{a.gene\_symbol}}* | | {%p if “>” in a.hgvs\_c%}  SNV  {%p else%}  Indel  {%p endif%} | | {{a.transcript\_primary}} | | {{a.gene\_region}} | {{a.hgvs\_c}} | | {{a.hgvs\_p}} | {{a.freq\_str}} | |
| {%tr endfor%} | | | | | | | | | | | |
| {%tr else%} | | | | | | | | | | | |
| 未检出 | 未检出 | | 未检出 | | 未检出 | | 未检出 | 未检出 | | | 未检出 |
| {%tr endif%} | | | | | | | | | | | |

* **Fusion检测结果**

|  |  |  |  |
| --- | --- | --- | --- |
| **基因** | **转录本** | **融合类型** | **拷贝数/突变丰度** |
| {%tr if (var.var\_somatic.level\_I+var.var\_somatic.level\_II+var.var\_somatic.level\_onco\_nodrug)|filter\_sv%} | | | |
| {%tr for a in (var.var\_somatic.level\_I+var.var\_somatic.level\_II+var.var\_somatic.level\_onco\_nodrug)|filter\_sv%} | | | |
| *{{a.gene\_symbol}}* | {{a.five\_prime\_transcript}}  {{a.three\_prime\_transcript}} | {{a.five\_prime\_gene}}:{{a.five\_prime\_region}}-{{a.three\_prime\_gene}}:{{a.three\_prime\_region}} | {{a.freq\_str}} |
| {%tr endfor%} | | | |
| {%tr else%} | | | |
| 未检出 | 未检出 | 未检出 | 未检出 |
| {%tr endif%} | | | |

**编制人： 复核人：**

注：

1. 本报告仅报告致癌性和疑似致癌性位点。

2. 本报告仅针对本次送检标本，该检测为肿瘤患者个体化治疗提供参考，治疗方案由医生决策**。**

**数据质控**

|  |  |  |  |
| --- | --- | --- | --- |
| **质控内容** | | **质控标准** | **质控结果** |
| cfDNA质控 | cfDNA 浓度 | ≥0.1ng/µL | {{lib\_quality\_control.lib\_dna\_qc.dna\_concn|replace(“.00”, “”)}} |
| cfDNA总量 | ≥5ng | {{lib\_quality\_control.lib\_dna\_qc.dna\_qty|replace(“.00”, “”)}} |
| 文库质控 | 预文库浓度 | ≥16.7ng/µL | {{ lib\_quality\_control.lib\_dna\_qc.dna\_pre\_library\_concentration|replace(“.00”, “”)}} |
| 捕获文库浓度 | ≥2.5ng/µL | {{ lib\_quality\_control.lib\_dna\_qc.dna\_fnl\_library\_concentration|replace(“.00”, “”)}} |
| 数据质控 | CleanQ30 | ≥75% | {{qc.dna\_data\_qc.cleandata\_q30|replace(“.00%”, “%”)}} |
| 覆盖度 | ≥95% | {{qc.dna\_data\_qc.cover\_ratio|replace(“.00%”, “%”)}} |
| 有效测序深度≥950x的热点占比例 | ≥95% | {{qc.dna\_data\_qc.coverage\_ratio\_uniq\_hot|replace(“.00%”, “%”)}} |

* **名词解释**

Q30: 测序的准确率高于99.9%的碱基的比例

覆盖度：检测到的区域占目标区域的比例

有效测序深度≥950x的热点比例：去重平均深度≥950x的热点区域占目标热点区域的比例